Guangzhou Wondfo Biotech300482.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Guangzhou Wondfo Biotech (300482.SZ) trades at a negative P/E (-56.89x, due to a recent net loss), P/B of 1.39x, P/S of 3.55x, and a dividend yield of 1.39%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 1st percentile over the trailing 10Y window (vs. 3rd percentile over 3Y); P/S sits at the 18th percentile over the trailing 10Y window (vs. 24th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 17th percentile within its industry and the 18th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.80%, ranking at the 81st percentile over the trailing 20Y window.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 1.39% comes from cash dividends, with an implied ~0.41% from buybacks — a fairly balanced mix of both channels. Guangzhou Wondfo Biotech operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 300482 · SZSE: 300482 · 300482
Want the full picture on whether Guangzhou Wondfo Biotech (300482.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -56.89 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 1.39 | ||||||
| P/S (TTM) | 3.55 | ||||||
| Dividend Yield | 1.39% | ||||||
| Buyback + Div Yield | 1.80% |